X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs CADILA HEALTHCARE - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD CADILA HEALTHCARE BIOCON LTD/
CADILA HEALTHCARE
 
P/E (TTM) x 82.9 32.1 258.0% View Chart
P/BV x 7.8 6.0 130.6% View Chart
Dividend Yield % 0.2 0.8 20.2%  

Financials

 BIOCON LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
CADILA HEALTHCARE
Mar-17
BIOCON LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,162460 252.6%   
Low Rs483305 158.2%   
Sales per share (Unadj.) Rs194.692.1 211.2%  
Earnings per share (Unadj.) Rs34.414.8 232.2%  
Cash flow per share (Unadj.) Rs48.318.5 261.2%  
Dividends per share (Unadj.) Rs1.003.20 31.3%  
Dividend yield (eoy) %0.10.8 14.5%  
Book value per share (Unadj.) Rs241.968.0 355.8%  
Shares outstanding (eoy) m200.001,023.74 19.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.2 101.8%   
Avg P/E ratio x23.925.8 92.6%  
P/CF ratio (eoy) x17.020.7 82.3%  
Price / Book Value ratio x3.45.6 60.4%  
Dividend payout %2.921.6 13.5%   
Avg Mkt Cap Rs m164,440391,581 42.0%   
No. of employees `0009.216.9 54.8%   
Total wages/salary Rs m7,47015,002 49.8%   
Avg. sales/employee Rs Th4,213.95,594.5 75.3%   
Avg. wages/employee Rs Th809.0890.1 90.9%   
Avg. net profit/employee Rs Th745.2899.9 82.8%   
INCOME DATA
Net Sales Rs m38,91194,295 41.3%  
Other income Rs m1,5711,286 122.2%   
Total revenues Rs m40,48295,581 42.4%   
Gross profit Rs m9,79519,036 51.5%  
Depreciation Rs m2,7723,750 73.9%   
Interest Rs m260450 57.8%   
Profit before tax Rs m8,33416,122 51.7%   
Minority Interest Rs m163338 48.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,6161,289 125.4%   
Profit after tax Rs m6,88115,168 45.4%  
Gross profit margin %25.220.2 124.7%  
Effective tax rate %19.48.0 242.5%   
Net profit margin %17.716.1 109.9%  
BALANCE SHEET DATA
Current assets Rs m40,47760,223 67.2%   
Current liabilities Rs m16,78353,058 31.6%   
Net working cap to sales %60.97.6 801.4%  
Current ratio x2.41.1 212.5%  
Inventory Days Days6070 85.4%  
Debtors Days Days8388 94.0%  
Net fixed assets Rs m45,07372,984 61.8%   
Share capital Rs m1,0001,024 97.7%   
"Free" reserves Rs m47,37768,576 69.1%   
Net worth Rs m48,37769,600 69.5%   
Long term debt Rs m21,08224,684 85.4%   
Total assets Rs m93,942152,207 61.7%  
Interest coverage x33.136.8 89.8%   
Debt to equity ratio x0.40.4 122.9%  
Sales to assets ratio x0.40.6 66.9%   
Return on assets %7.610.3 74.1%  
Return on equity %14.221.8 65.3%  
Return on capital %12.617.9 70.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98821,280 61.0%   
Fx outflow Rs m7,89910,874 72.6%   
Net fx Rs m5,08910,406 48.9%   
CASH FLOW
From Operations Rs m6,40013,495 47.4%  
From Investments Rs m-4,985-29,103 17.1%  
From Financial Activity Rs m-1,77523,158 -7.7%  
Net Cashflow Rs m-4737,556 -6.3%  

Share Holding

Indian Promoters % 40.4 74.8 54.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.3 101.2%  
FIIs % 10.7 5.9 181.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 11.0 180.9%  
Shareholders   109,995 44,069 249.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS